Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound - Janoschka, Claudia; Lindner, Maren; Koppers, Nils; Starost, Laura; Liebmann, Marie; Eschborn, Melanie; Schneider-Hohendorf, Tilman; Windener, Farina; Schafflick, David; Fleck, Ann-Katrin; Koch, Kathrin; Deffner, Marie; et al. (Proceedings of the National Academy of Sciences - PNAS, 2023)
Keywords: Animals; Apoptosis; Biological Sciences; Brain; Brain damage; CCR6 protein; Cerebrospinal fluid; Helper cells; Histology; Inflammation; Interleukin 17; Lymphocytes T; Mice; Multiple sclerosis; Multiple Sclerosis - cerebrospinal fluid; Multiple Sclerosis - drug therapy; Natalizumab - pharmacology; Natalizumab - therapeutic use; Pathogenicity; Pathogens; Pathophysiology; Patients; Peripheral blood; Risk assessment; Th17 Cells; Virulence; pathogenicity; disease rebound; multiple sclerosis; natalizumab; Th17 cells